All research presented at ACG 2025 is strictly embargoed until 12:00 pm local Arizona Time, which aligns with Pacific Daylight Time (PDT)/3:00 pm ET on Sunday, October 26, 2025.
Oral 8 – Associations Between Early Fluid Resuscitation, SIRS Status, and BUN Changes in Acute Pancreatitis: Real World Results From the APPRENTICE Consortium
Monday, October 27, 2025 | 9:54 AM – 10:06 AM PDT | North Ballroom 120D
Author Insight from Daniel Marino, MD, MBA
What’s new here and important for clinicians?
Modifying IV fluid rates is unlikely to prevent new/persistent SIRS, severe acute pancreatitis, pancreatic necrosis, or organ failure. Among patients with indicators of a more severe disease course, such as new or persistent SIRS or an increase in BUN, higher IV fluid rates were more frequently administered to those who developed severe acute pancreatitis. Although more severely ill patients tended to receive higher fluid rates, their outcomes were likely driven by SIRS which appears unresponsive to fluid therapy. Future interventions should focus on targeting SIRS through novel therapeutic approaches.
What do patients need to know?
The treatment of acute pancreatitis continues to evolve. Traditional strategies may need optimization to improve patient outcomes. Novel therapeutic approaches will be necessary to achieve better results.
Author Contact
Daniel Marino, MD, MBA
NYU Langone Health
New York, NY
daniel.marino [at] nyulangone.org
For assistance contacting other ACG experts, please contact Becky Abel, ACG’s Senior Communications Manager, at mediaonly [at] gi.org.